RNA Therapies in Oncology Analysis 2022: Coverage of 127 Companies Plus Partners Developing 274 RNA Therapy Drugs with 182 in Active Development Across 122 Different Targets – QNT Press Release


DUBLIN, July 21, 2022 /PRNewswire/ — The “RNA Therapies in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

RNA Therapies in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of ​​oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your RNA therapy drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

RNA therapies, such as miRNA, RNAi & siRNA, is an emerging class of biopharmaceutical that has immense potential in cancer medicine. Critical to the field, recent developments in delivery technologies such nanoparticle carriers and conjugation strategies have allowed RNA therapeutics to enter clinical trials in the treatment of cancer.

Your RNA Therapies in Oncology: Analytical Tool covers more than 127 companies plus partners who are today developing 274 RNA therapy drugs where of 182 are in active development in cancer across 122 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

For 20 years we have supported better decision making across the oncology drug development industry. Your RNA Therapies in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer’s desktop into a high capacity workbench within your area of ​​choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center